Research lines


Molecular design , structural design , synthesis and Bioassessment of new drug candidates:

The research interests of the Laboratory of Bioactive Substances Assessment and Synthesis (LASSBio®) are located in Medicinal Chemistry, with the multidisciplinary research line rational identification new drug candidates for the treatment of various pathophysiological conditions, especially for chronic inflammatory diseases such as rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (DOPC) and silicosis. Some projects under consideration in LASSBio® address the identification of new compounds prototypes for the treatment of leishmaniasis and Chagas' disease, neglected diseases that are among those targeted disease studies in our laboratory. Participation response inflammatory in the etiology of non-communicable chronic degenerative diseases such as diabetes, cancer, Alzheimer's and schizophrenia, motivated LASSBio® studying projects adopting these areas molecular design strategies based on the receiver structure (SBDD) or binder (LBDD) beyond the use of rational combination of molecular fragments, including the use of bióforos natural. The new substances once synthesized and structurally characterized, when State of suitable purity are subjected to bioassays, in addition to having its physical properties Chemical investigated as solubility and chemical stability in vitro and in vivo as well as investigate, In some cases, the plasma and hepatic microsomal metabolism in vitro, with consequent characterization of the metabolites formed, and his prediction in silico. The LASSBio® has Chemo with over 1800 unique compounds belonging to different chemical classes, eg N-acilidrazonas, sulfonilidrazonas, semicarbazones, phthalimides, functionalized phenyl-pyrazoles and other various patterns Structural defining new prototypes with wide chemodiversity protected activities hypoglycemic, anti-arthritis, antineoplastic, antipsychotic, analgesic, antiasthmatic, among others.